Dr. Elias Obeid on Androgen Receptor Expression in Triple-Negative Breast Cancer

Elias Obeid, MD, MPH
Published: Tuesday, Mar 08, 2016



Elias Obeid, MD, MPH, assistant professor, Department of Clinical Genetics, Fox Chase Cancer Center, discusses a retrospective analysis that investigated androgen receptor expression in patients with triple-negative breast cancer. (TNBC).

Androgen receptor expression was present in about 17% of patients analyzed in the study, says Obeid. In androgen receptor-negative TNBC, also know as quadruple-negative breast cancer (QNBC), overexpression of EGFR and loss of PTEN seemed to be more common compared with androgen receptor-positive TNBC. This opens the door for potential targeted therapies, says Obeid.

In androgen receptor-positive TNBC, it was determined that there was low expression of TS and TUBB3, and overexpression of several other genes. Based on these findings, oncologists should consider treating these patients with combination chemotherapy and targeted therapy agents, says Obeid.

SELECTED
LANGUAGE


Elias Obeid, MD, MPH, assistant professor, Department of Clinical Genetics, Fox Chase Cancer Center, discusses a retrospective analysis that investigated androgen receptor expression in patients with triple-negative breast cancer. (TNBC).

Androgen receptor expression was present in about 17% of patients analyzed in the study, says Obeid. In androgen receptor-negative TNBC, also know as quadruple-negative breast cancer (QNBC), overexpression of EGFR and loss of PTEN seemed to be more common compared with androgen receptor-positive TNBC. This opens the door for potential targeted therapies, says Obeid.

In androgen receptor-positive TNBC, it was determined that there was low expression of TS and TUBB3, and overexpression of several other genes. Based on these findings, oncologists should consider treating these patients with combination chemotherapy and targeted therapy agents, says Obeid.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x